Mercer Global Advisors
PDSB icon

Mercer Global Advisors’s PDS Biotechnology PDSB Stock Holding History

Mercer Global Advisors’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,500
Closed -$12.6K – 2942
2025
Q3 		$12.6K Sell
12,500
-10
-0.1% -$12 ﹤0.01% 2627
2025
Q2 		$16.6K Buy
12,510
+10
+0.1% +$14 ﹤0.01% 2227
2025
Q1 		$14.9K Hold
12,500
– – ﹤0.01% 2134
2024
Q4 		$20.4K Hold
12,500
– – ﹤0.01% 2105
2024
Q3 		$45.6K Hold
12,500
– – ﹤0.01% 1922
2024
Q2 		$36.6K Hold
12,500
– – ﹤0.01% 1925
2024
Q1 		$50K Hold
12,500
– – ﹤0.01% 1896
2023
Q4 		$62K Hold
12,500
– – ﹤0.01% 1942
2023
Q3 		$63K Sell
12,500
-12,500
-50% -$68.5K ﹤0.01% 1885
2023
Q2 		$126K Buy
+25,000
New +$164K ﹤0.01% 1802

Other funds holding PDSB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mercer Global Advisors's PDSB Position: Q4 2025 in Review

Mercer Global Advisors sold out of PDS Biotechnology (PDSB) in Q4 2025, closing a stake of 12,500 shares — an estimated $12.6K sold.

Mercer Global Advisors first reported a position in PDSB in Q2 2023 and held it in 10 quarters. The position peaked at $126K in Q2 2023. 44 funds tracked by Wall St. Rank hold PDSB as of Q4 2025.

  • Mercer Global Advisors reported no remaining PDS Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Mercer Global Advisors sold 12,500 PDS Biotechnology shares in Q4 2025, an estimated $12.6K.
  • Mercer Global Advisors first reported a position in PDS Biotechnology in Q2 2023 and held it in 10 quarters.
  • Mercer Global Advisors's PDS Biotechnology position peaked at $126K in Q2 2023.
  • 44 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2025.

Based on Mercer Global Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.